HF4493

Purpose

• Expand the role of pharmacists to help treat opioid use disorder (OUD) by allowing them to initiate, prescribe, administer, and dispense certain medications for OUD.
• Update grounds for disciplinary action against pharmacists and pharmacist interns, clarifying and adding circumstances that can lead to sanctions or license actions.

Main provisions (what the bill would do)

• Expanded definition of who is a practitioner: Pharmacists are explicitly included as practitioners who can prescribe or administer certain medications under specific rules.
• Treatment of opioid use disorder by pharmacists:
  • A pharmacist may prescribe, administer, and dispense drugs in Schedules III–V to treat OUD, if certain conditions are met (e.g., medically indicated treatment and proper documentation in the patient’s health record).
  • Pharmacists must complete a training program specifically for treating substance use disorders and obtain the appropriate federal DEA registration for the schedules involved.
  • Before dispensing, the pharmacist must provide counseling on proper use, follow-up needs, and any required information per state rules.
  • A pharmacist cannot delegate the authority to prescribe; an intern may prepare the prescription, but a licensed pharmacist must review, approve, and sign it.
  • Pharmacists may participate in initiation, management, modification, and discontinuation of OUD therapy according to a protocol or collaborative practice agreement with other licensed prescribers (e.g., dentists, physicians, physician assistants, podiatrists, veterinarians, nurse practitioners, etc.).
  • Any changes in drug therapy made under a protocol must be documented in the patient’s medical record or reported to the supervising practitioner.
• Protocols and collaboration:
  • The bill allows formal protocols or collaborative practice agreements to govern how pharmacists initiate, adjust, or stop therapy for OUD.
• Vaccinations and immunizations:
  • Pharmacists may administer certain vaccines, including influenza and COVID-19 (or SARS-CoV-2) vaccines to eligible individuals, under specified training and reporting requirements (e.g., using the Minnesota Immunization Information Connection to check immunization status and to report administration).
  • Certain supervision and training requirements apply for pharmacy technicians or interns who administer vaccines.
• Expanded clinical activities under protocol:
  • Pharmacists may initiate or modify therapy for other conditions under protocols with other healthcare professionals (dentists, optometrists, physicians, physician assistants, podiatrists, veterinarians, etc.), and must document changes in the patient’s medical record.
• Controlled substances prescription rules:
  • The bill updates prescription requirements for Schedule III–IV drugs to include more flexible prescribing by pharmacists under the new authority, with limits such as a maximum six-month supply and a cap on refills (up to five), subject to prescriber consent and other safeguards.
• Pharmacist authority to prescribe/dispense controlled substances (new subdivision):
  • A pharmacist may prescribe, administer, and dispense controlled substances in Schedules III–V under the authority created in the bill, with the possibility for a pharmacist intern to assist under supervision.
• Other practice and safety provisions:
  • Grounds for disciplinary actions include fraud, noncompliance with licensure requirements, unprofessional conduct, violations of board orders, failure to report required information, and actions that undermine patient safety or qualifying standards of care.
  • The board may delay issuing a license or registration if there are pending disciplinary actions or felonies, or if related actions are underway in other states.

Significant changes to existing law

• New explicit authority for pharmacists to treat OUD with Schedule III–V medications, including required training and DEA registration.
• mandatory documentation in patient health records for changes in therapy made under protocols or collaborative agreements.
• formal inclusion of pharmacists in vaccination programs with defined supervision and training requirements.
• broad expansion of the scope of pharmacist practice through protocols and collaborations with a wider range of health professionals.
• revised grounds for disciplinary action to cover a broader set of professional conduct issues and cross-state actions.
• revised prescription rules for controlled substances to allow pharmacist-driven prescribing, administration, and dispensing under the new framework, with defined limits and reporting requirements.

Definitions and scope (important concepts)

• Opioid use disorder (OUD): The condition being treated with the expanded pharmacist role.
• Practitioner: Expanded to include pharmacists who meet the defined requirements for prescribing under this bill.
• Protocol and collaborative practice agreement: The mechanisms by which pharmacists may initiate, modify, or discontinue drug therapy in collaboration with other licensed prescribers.
• Schedules III–V: The controlled substances involved in the expanded pharmacist authority for OUD treatment, subject to training and regulatory compliance.
• DEA registration: Federal registration required for prescribing certain controlled substances.
• Counseling and health-record documentation: Required steps to ensure patient understanding and continuity of care.

Relevant Terms - opioid use disorder - pharmacist - prescribe - administer - dispense - Schedule III through V - training program (for substance use disorders) - DEA registration - protocol - collaborative practice agreement - patient health record - counseling - vaccination/immunization - Minnesota Immunization Information Connection - intramuscular and subcutaneous administration (where applicable) - opiate antagonists - self-administered hormonal contraceptives - nicotine replacement medications - HIV prevention (drug therapy to prevent HIV) - treatment plan - interdisciplinary collaboration - disciplinary action/grounds for discipline - license/registration delays or actions